Global Pharmacogenetic Testing Market - Industry Trends and Forecast to 2030

Global Pharmacogenetic Testing Market - Industry Trends and Forecast to 2030

The global pharmacogenetic testing market is expected to reach USD 11,442.40 million by 2030 from USD 5,960.00 million in 2022, growing at a CAGR of 8.7% during the forecast period of 2023 to 2030.

Market Segmentation
Global Pharmacogenetic Testing Market, By Type (Whole Genome Sequencing, Whole Exome Sequencing, Array-Based Tests, and Single Gene Tests), Gene Type (CYP2C19, CYP2D6, CYP2C9 AND VKORC1, CYP1A2, HLA-B*1502, HLA-B*5701, CYP2D, OPRM1, ONCOTYPE DX AND MAMMAPRINT, DRD3, D4D4, SLC6A4, HTR2A/C, TMPT, and Others), Drug Type (Prescription Drugs, Nutraceuticals, Recreational Drugs, Herbal Supplements, Vitamins, and Over-the-Counter Medications), Sample (Blood and Saliva), Therapeutic Area (Cardiology, Gastroenterology, Anesthesiology, Genomics, Endocrinology, Immunology & Hypersensitivity, Dermatology, Gynecology, Oncology, Neurology, and Others), Application (Clinical Practice, Drug Development, and Drug Regulation), End User (Healthcare Providers, Pharmaceutical & Biotechnology Companies, Research Centres and Academic Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacies, Mail-Order Pharmacies, and Direct-to-Customer Services), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, rest of Middle East and Africa) - Industry Trends and Forecast to 2030.

Overview of Global Pharmacogenetic Testing Market Dynamics

Driver
• Rapid technological advancement and miniaturization
Restrain

• Environment and health concerns
Opportunity

• Rising research and development and innovative technologies

Market Players

Some of the major market players operating in the global pharmacogenetic testing market are:

• Thermo Fisher Scientific
• Illumina, Inc
• QIAGEN
• Sonic Healthcare
• BGI
• PerkinElmer Genomics
• Eurofins Scientific
• 23andMe Holding Co.
• GENEWIZ (A subsidiary of Azenta Life Sciences)
• Luminex Corporation. (A subsidiary of DiaSorin S.p.A.)
• PacBio.
• Assurex Health, Inc. (A subsidiary of Myriad Genetics)
• MD Labs
• OneOme, LLC
• Dynamic DNA Laboratories
• PGXT Show more